Viewing Study NCT06194695

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:03 PM
Ignite Modification Date: 2026-02-01 @ 6:40 AM
Study NCT ID: NCT06194695
Status: RECRUITING
Last Update Posted: 2024-01-09
First Post: 2023-12-22
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
Sponsor: Ze-yang Ding, MD
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cholangiocarcinoma Non-resectable View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Intrahepatic Cholangiocarcinoma View
None Lenvatinib View
None DEB-TACE View
None anti-PD(L)1 antibodies View